| P50 | author | Robert J. Wilkinson | Q30423489 |
| | David R. Boulware | Q39519469 |
| | Nathan C. Bahr | Q49391744 |
| | Graeme Meintjes | Q55098484 |
| | Suzaan Marais | Q84135757 |
| P2093 | author name string | James Scriven | |
| P2860 | cites work | Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study | Q21144623 |
| | Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings | Q24600270 |
| | Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain | Q24619923 |
| | Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons | Q24628614 |
| | Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome | Q24630287 |
| | Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies | Q28256960 |
| | Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings | Q28749315 |
| | Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS | Q29617372 |
| | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| | The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment | Q31104394 |
| | PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids | Q33398308 |
| | Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa | Q33871884 |
| | Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults | Q33982474 |
| | Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy | Q34041795 |
| | Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome | Q34130659 |
| | Neuroradiological features of the tuberculosis-associated immune reconstitution inflammatory syndrome | Q34251655 |
| | Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions | Q34516548 |
| | Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction | Q34730629 |
| | A Case report: Herpes zooster IRIS in pregnancy | Q34781005 |
| | Central nervous system disorders after starting antiretroviral therapy in South Africa | Q34799534 |
| | Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy | Q34808562 |
| | Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART) | Q34875897 |
| | Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis | Q35121804 |
| | Integration of antiretroviral therapy with tuberculosis treatment | Q35600960 |
| | Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome | Q35622163 |
| | Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control | Q35758657 |
| | Timing of antiretroviral therapy for HIV-1 infection and tuberculosis | Q35890799 |
| | Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS | Q35938575 |
| | Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation | Q36187510 |
| | Metabolic profile of PML lesions in patients with and without IRIS: an observational study | Q36198630 |
| | Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome | Q36238260 |
| | Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. | Q36292469 |
| | New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab | Q36422537 |
| | Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none | Q36426562 |
| | Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome | Q36517790 |
| | Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy | Q36752233 |
| | Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis | Q36934339 |
| | The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana | Q36991683 |
| | Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy | Q37028699 |
| | Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein | Q37104090 |
| | Cerebrospinal fluid miRNA profile in HIV-encephalitis. | Q37141244 |
| | Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial | Q37189075 |
| | Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis | Q37718319 |
| | Cryptococcal immune reconstitution syndrome during steroid withdrawal treated with hydroxychloroquine. | Q37811287 |
| | Immune reconstitution inflammatory syndrome mimicking relapsing cryptococcal meningitis in a renal transplant recipient | Q37821090 |
| | Immune reconstitution inflammatory syndrome and the central nervous system | Q37866038 |
| | Management of the immune reconstitution inflammatory syndrome. | Q38023242 |
| | Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa | Q38374183 |
| | Changing incidence of central nervous system diseases in the EuroSIDA cohort | Q38479888 |
| | Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda | Q38877605 |
| | Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults | Q38884510 |
| | Immune reconstitution inflammatory syndrome (IRIS) associated with Cryptococcus neoformans infection in AIDS patients | Q39288782 |
| | Central nervous system-immune reconstitution inflammatory syndrome in resource-limited settings: current burden and future needs | Q39588638 |
| | Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort | Q39724313 |
| | Severe leukoencephalopathy with fulminant cerebral edema reflecting immune reconstitution inflammatory syndrome during HIV infection: a case report | Q42007355 |
| | Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome | Q42269599 |
| | Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study | Q43291844 |
| | When to start antiretroviral therapy in HIV-associated tuberculosis. | Q43567066 |
| | The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. | Q43716016 |
| | Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. | Q45363437 |
| | Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study | Q46051910 |
| | Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab | Q46145188 |
| | The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. | Q46172301 |
| | Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort | Q46172571 |
| | An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients | Q46503386 |
| | CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity | Q46504313 |
| | Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital | Q47586850 |
| | Paradoxical reaction during treatment of tuberculous brain abscess in a patient with AIDS. | Q48250477 |
| | Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients | Q48452725 |
| | A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis | Q48488503 |
| | Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes | Q48891027 |
| | Immunological and clinical consequences of treating a patient with natalizumab | Q48906242 |
| | Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. | Q50553161 |
| | Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. | Q51869965 |
| | HIV-associated cryptococcal meningitis. | Q55046805 |
| | Prevalence, Determinants of Positivity, and Clinical Utility of Cryptococcal Antigenemia in Cambodian HIV-Infected Patients | Q56830151 |
| | Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS | Q56839116 |
| | Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study | Q57393061 |
| | Phased implementation of screening for cryptococcal disease in South Africa | Q59115007 |
| | Case report. Toxoplasma encephalitis after initiation of HAART | Q77534205 |
| | Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART | Q79929037 |
| | Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis | Q80808509 |
| | Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France | Q81857130 |
| | The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis | Q83769007 |
| | Is the diagnosis at hand? | Q83934885 |
| | Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT | Q84412684 |
| | Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy | Q85180313 |
| | PML in a patient treated with fumaric acid | Q86649822 |
| P433 | issue | 6 | |
| P921 | main subject | inflammation | Q101991 |
| | nervous system | Q9404 |
| P304 | page(s) | 583-593 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | Current infectious disease reports | Q26842136 |
| P1476 | title | Central nervous system immune reconstitution inflammatory syndrome | |
| P478 | volume | 15 | |